Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Haber

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Oncotarget|June 19, 2016
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangementsKlaartje Somers, Daria A Chudakova, Shiloh M C Middlemiss, et al.
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
British Journal of Cancer|September 18, 2018
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade gliomaDavid S Ziegler, Marie Wong, Chelsea Mayoh, et al.
International Journal of Cancer|April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancerMoonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Cold Spring Harbor Molecular Case Studies|November 4, 2020
Recurrent <i>SPECC1L-NTRK</i> fusions in pediatric sarcoma and brain tumorsDong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine TrialRebecca Daly, Kate Hetherington, Emily Hazell, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Oncotarget|June 19, 2016
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangementsKlaartje Somers, Daria A Chudakova, Shiloh M C Middlemiss, et al.
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
British Journal of Cancer|September 18, 2018
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade gliomaDavid S Ziegler, Marie Wong, Chelsea Mayoh, et al.
International Journal of Cancer|April 12, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancerMoonsun Jung, Jixuan Gao, Leanna Cheung, et al.
Nature Medicine|September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastomaAlexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Science Advances|November 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastomaJeremy Z R Han, Monica Phimmachanh, Jordan F Hastings, et al.
Cold Spring Harbor Molecular Case Studies|November 4, 2020
Recurrent <i>SPECC1L-NTRK</i> fusions in pediatric sarcoma and brain tumorsDong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, et al.
Journal of Personalized Medicine|July 29, 2023
Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine TrialRebecca Daly, Kate Hetherington, Emily Hazell, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivoJayne Murray, Emanuele Valli, Denise M T Yu, et al.
Pageof 19